To better understand the mechanisms and the potential interconnections between pancreatitis, diabetes, and pancreatic ductal adenocarcinoma (PDAC), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Cancer Institute (NCI) cosponsored a workshop in Bethesda, MD, on June 12 to 13, 2013. The workshop was designed to bring together experts from academic institutions, industry, and government agencies to present relevant data and perspectives on questions related to the risk and the development of pancreatic cancer.
Twenty-seven presenters and 7 discussants were joined by 21 poster presentations (the complete agenda and list of presenters are available as supplementary material at http://links.lww.com/MPA/A252). The workshop was dedicated to the memory of George S. Eisenbarth, MD, PhD, a visionary mentor and investigator in the field of diabetes who died of pancreatic cancer in November 2012. The program included 6 sessions: (1) Statement of the Problem of PDAC, (2) Pancreatitis as a Risk Factor for PDAC, (3) Diabetes as a Risk Factor for PDAC, (4) Pancreatogenic (Type 3c) Diabetes, (5) Surveillance of High-Risk Populations and Early Detection of PDAC, and (6) Effects of DM Treatment on PDAC. In addition, the workshop included state-of-the-art lectures on Overview of PDAC and on Genomic Associations of Chronic Pancreatitis, Diabetes Mellitus, and PDAC. The high points of each session are summarized below.
OVERVIEW OF THE PROBLEM
In contrast to dramatic declines in cancer-related deaths from other malignancies (ie, lung and bronchus, breast, colorectal, and prostate cancer), progress in the management of PDAC has been slow, and the incidence of deaths due to PDAC continues to rise.1 The known risk factors of PDAC include tobacco exposure, long-standing diabetes, obesity, advanced age, exposure to benzenes, family history, and chronic pancreatitis2 (CP; Table 1). It is generally believed that unless the cancer risk in a given population increases 8- to 10-fold over average risk, there is no cost-benefit advantage to screening. In selected syndromes such as familial pancreatic cancer, Peutz-Jeghers syndrome, familial atypical mole and melanoma syndrome, and familial pancreatitis or in selected families with BRCA mutations, the risk does approach or exceed this threshold. In these circumstances, screening with either endoscopic ultrasound (EUS) or magnetic resonance imaging (MRI) is justified.3
On the molecular level, the driving oncogene for this malignancy seems to be K-ras.4 In addition to activating mutations of this gene, other pathways are frequently suppressed, such as p16, p53, and DPC4. However, a family history is still more important than mutation screening for predicting the risk for PDAC. Precursor lesions for invasive disease include pancreatic intraepithelial neoplasms (PanINs) or benign tumors with malignant potential, such as intraductal papillary mucinous neoplasms (IPMNs) or mucinous cystic neoplasms. Histologically, the invasive malignant lesion is dominated by an intense desmoplastic stroma, and the role of the stromal compartment is incompletely understood but thought to play a major role in the aggressive behavior of this malignancy. It has been suggested that the desmoplastic stroma may be a barrier to effective drug delivery. Although new chemotherapy regimens, such as FOLFIRINOX or gemcitabine plus nab-paclitaxel, have been introduced, these regimens are not free of toxicity and add little to long-term survival. For these reasons, a better understanding of the unique characteristics of PDAC is needed to improve early detection, treatment, and prevention.
CHRONIC PANCREATITIS AS A RISK FACTOR OF PDAC
Understanding the common pathways for CP and PDAC may help to identify high-risk patients and facilitate the development of effective screening tools. Epidemiologically, pancreatitis can be considered as a disease continuum: starting with an attack of acute pancreatitis (AP), leading to recurrent AP in some patients (approximately 20%-30%), then progression to CP in some (approximately 10%), and ultimately development of PDAC in a subset of patients with CP.5 Risk for progression from AP to CP seems to be higher in patients with a history of continuous tobacco smoking or alcohol drinking.5 However, the precise risk factors and mechanisms involved with this progression have yet to be determined.
One of the challenges in epidemiology studies of pancreatitis and/or diabetes with PDAC is “reverse causality.”6 Although long-standing CP clearly increases the risk for PDAC, PDAC also causes AP and CP. Likewise, although long-standing diabetes increases the risk for PDAC, PDAC itself causes glucose intolerance and diabetes as a paraneoplastic process. Thus, great care must be given in evaluating the timing, context, and comparison groups in epidemiology and database studies of PDAC risk association and causality.
Environmental and genetic factors contribute to the risk for AP, CP, and PDAC, with hereditary CP clearly having the largest genetic contribution.6 Familial studies and candidate gene testing have established PRSS1, SPINK1, CTRC, CFTR, CASR, and GGT1 as susceptibility loci for CP (see Genomic Associations below). Recently, a large 2-stage GWAS analysis identified and replicated PRSS1-PR SS2 and X-linked CLDN2 as susceptibility loci for CP.7 The highest cancer risks have been observed in patients with hereditary pancreatitis (HP)—a rare genetic form of pancreatitis with mutations of the cationic trypsinogen gene (PRSS1) with an onset at an early age. In subjects with HP, the risk for PDAC is approximately 50 times greater than in the corresponding background population, and the lifetime risk for developing PDAC8 is approximately 70%, although the lifetime risk in nonsmokers with HP9 may be less than 20%.
The inflammatory milieu is important in both CP and PDAC, and there is evidence that this component may promote the epithelial-to-mesenchymal transition of pancreatic cells,10 which is a component of oncogenesis. In KRASG12D-engineered mice, PanIN lesions have been associated with acinar-to-ductal metaplasia (ADM),11,12 a condition in which the phenotypic characteristics of the acinar cells are changed and cells express ductal markers such as CK19 and Sox9.13,14 Inducing even 1 episode of AP in mice with KRASG12D mutation may lead to feed-forward activation loops with persistent NF-κb activation (a proinflammatory, antiapoptotic mediator), with a marked increase in PDAC development.15,16 These recent findings provide a possible mechanistic pathway between chronic inflammation and PDAC.
The Role of Stellate Cell Activation in PDAC
Pancreatic stellate cells (PSCs) constitute roughly 4% of all pancreatic cells and are thought of as specialized myofibroblasts that are regulated by autocrine and paracrine stimuli.17,18 Pancreatic stellate cells promote tumor progression, metastasis, and resistance to chemotherapy and thus play a central role in PDAC (as well as CP). These specialized cells are now known to be activated by ethanol and its metabolites and by several factors that are upregulated during pancreatic injury including growth factors, cytokines, and oxidant stress. Conditioned media from cultured PSCs can also alter apoptosis—the result being protection of pancreatic cancer cells from chemo- and radiation-induced apoptosis. Furthermore, the dense network of collagen and other matrix proteins may prevent circulating chemotherapeutic agents from reaching PDAC cells. Strategies are being developed to circumvent the protective barrier for PDAC cells that are generated by PSCs and improve delivery of therapeutic agents to the target.
Role of Cholecystokinin in PDAC Development
The gastrointestinal peptide cholecystokinin (CCK) and the related peptide gastrin act on CCK receptors to regulate pancreatic digestive enzyme release, gastric acid stimulation, and gastrointestinal tract growth. Cholecystokinin is released in response to dietary fat; epidemiologic studies show an increased incidence of CP in countries where fat consumption is high, and CCK blood levels have been reported to be elevated in patients with CP. Cholecystokinin-B receptors are the primary receptor type detected in the healthy human pancreas and are markedly overexpressed in pancreatic cancer.19 Cholecystokinin receptors have been identified on PSCs, and stimulation of these receptors produces collagen and fibrosis, features common to both CP and PDAC.20–22 In animal models, CCK receptors have been recently described on very early PanINs in mice,23 and receptor blockade halts PanIN progression and reverses fibrosis. A splice variant in the CCK-B receptor known as CCK-C has been identified in human PDAC, which results from a germline single nucleotide polymorphism (SNP).24
DIABETES AS A RISK FACTOR OF PDAC
Obesity, diabetes mellitus (DM), and glucose intolerance have all been associated with increased pancreatic cancer risk (Table 1). A study of 29,133 Finnish male smokers revealed that the presence of DM and, independently, elevated insulin concentrations both showed a significant 2-fold increased risk for the subsequent development of PDAC more than 10 years after baseline.25 These results support the hypothesis that exposure to higher insulin concentrations and insulin resistance affects the risk for exocrine pancreatic cancer.
These epidemiologic findings support the laboratory observations that PDAC is characterized by a constituitive overexpression of insulin receptors (IRs) and insulin-like growth factor receptors.26 The trophic effects of these enhanced signaling systems are also the target for the interaction of metformin in PDAC,27 which has attracted much recent interest.
Combined CP and Diabetes Risk on Pancreatic Cancer
A recent study from Taiwan indicated that the hazard ratio for subsequent PDAC in individuals with the combined factors of CP and diabetes was increased 33-fold over controls,28 but the forms of diabetes and CP were not further characterized. The ideal model to study this complex relationship is HP, a rare autosomal dominant inheritance disease caused by a mutation of the PRSS1 gene. Pancreatic insufficiencies occur early, and the median age at onset of exocrine insufficiency and diabetes is 29 and 38 years, respectively. Almost all patients experience these complications during their life-span. In patients with HP, the cumulative risk of PDAC at 50, 60, and 75 years is 10%, 19%, and 54%, respectively.29 Hereditary pancreatitis is associated with a high relative and absolute risk for PDAC as compared with the general population (standardized incidence ratio [SIR]: 87). Although only 26% of the patients in this French study developed DM, this complication was a major risk factor of PDAC within this cohort9,29 (RR, 13; 95% CI [confidence interval], 3–65). It is reasonable to assume that diabetes is a risk factor of PDAC rather than just being a symptom in patients with HP. However, it remains possible that diabetes is a surrogate marker for the severity of pancreatitis, and thus, the link to cancer is indirect.
In a separate study, pancreatic tissues from 43 patients with CP and 27 controls were examined by immunohistochemistry and quantitative morphometry. The pancreatic volumes were significantly reduced by approximately 20% in the patients with CP compared with the controls, and β-cell areas were 0.69% ± 0.08% in the patients with CP and 0.97% ± 0.08% in the controls, whereas α-cell areas did not differ between the groups. The lack of increased β-cell turnover in patients with CP, despite an approximately 10-fold increase in the number of apoptotic acinar cells, suggests that the damage to the pancreas is highly specific for the exocrine compartment and affects the endocrine islets to a lesser extent.30 However, recent reports suggest that β-cell dysfunction develops in the early stages of CP, whereas clinical diabetes manifests later, when there is profound fibrosis. This suggests that endocrine deficiency in CP is multifactorial. Although the role of transcription factors (such as pancreatic duodenal homeobox 1 [PDX-1], MafA, and NeuroD) on β-cell function is understood, alterations in these factors in CP have not been elucidated. Moreover, the role of PSCs on islet cell function is still poorly understood. Hyperglycemia and endothelin 1 have been reported to induce PSC activation, but the role of PSC activation on islet cell function remains unknown.
Role of PDX-1 in PDAC Development
Pancreatic duodenal homeobox 1 is a master regulator of embryologic pancreatic growth and development and regulates insulin expression and islet maintenance in the adult pancreas. However, it is also known that PDX-1 is an oncogenic transcription factor regulating PDAC. Therefore, PDX-1 is a potential therapeutic target in PDAC. Treatment with bifunctional human short hairpin RNA–PDX-1 significantly ablates human PDX-1–positive PDAC in SCID mice and prolongs survival, and a synthetic human insulin promoter drives expression of imaging genes in PDX-1–positive PDAC cell lines and tumors in mice.31 Systemic delivery of the bifunctional short hairpin RNA(PDX-1) resulted in marked reduction of tumor volume and improved survival in a human pancreatic cancer xenograft mouse model.32 Pancreatic duodenal homeobox 1 therefore seems to be a critical mediator of growth in healthy and neoplastic pancreatic tissue.
PANCREATOGENIC (TYPE 3c) DIABETES
Classification and Prevalence of Type 3c Diabetes Mellitus
Type 3c DM (T3cDM), also called pancreatogenic or apancreatic DM, and is a form of secondary or type 3 DM as defined by the American Diabetes Association and by the World Health Organization.33 The exocrine pancreatic diseases underlying T3cDM include acute and CP of any etiology, hemochromatosis, cystic fibrosis, fibrocalculous pancreatopathy, pancreatic trauma leading to loss of pancreatic tissue, pancreatectomy, pancreatic agenesis, and pancreatic cancer. The most common underlying disease is CP, accounting for approximately 75% to 80% of patients with T3cDM.34 Pancreatic carcinoma accounts for 8% of all T3cDM according to a recent study, but T3cDM also frequently occurs after surgical treatment of benign or malignant disease. Detailed data on T3cDM prevalence are scarce because of lack of research on the issue and difficulties with diabetes classifications.35
Older studies estimated T3cDM to have a low prevalence of approximately 0.5% to 1.2% among all cases of diabetes in North America, but recent data suggest that T3cDM might be more common than generally believed. In Germany, Ewald et al34 investigated 1868 diabetic patients seen at an academic medical center. After comprehensive evaluation, 9.2% of the patients could be classified as having T3cDM, using the American Diabetes Association criteria, of which 78% were also diagnosed with CP. Most of the patients with T3cDM were initially misclassified as having type 2 DM (T2DM). The previous underestimation of the prevalence of T3cDM might be due to the fact that it has become easier to detect exocrine pancreatic pathology because imaging methods of the pancreas have improved and noninvasive screening methods to quantify exocrine dysfunction, such as fecal elastase 1, are now widely available.35
In contrast to type 1 DM (T1DM) or T2DM, the endocrinopathy in T3cDM is complex and complicated by additional comorbidities such as maldigestion of fats and proteins and malnutrition. Exocrine insufficiency, a deficiency of fat-soluble vitamins (especially vitamin D), and impairments of fat hydrolysis and incretin secretion are found very commonly in T3cDM.36 Pancreatic enzyme replacement therapy is therefore required in virtually all patients with T3cDM.37
Treatment of T3cDM
Seventy-five percent of T3cDM is due to CP, which carries a high risk for pancreatic carcinoma. Insulin and insulin secretagogue treatment may increase the risk for malignancy, whereas metformin therapy may reduce it. Metformin should therefore be the first line of therapy, if tolerated, and continued if insulin treatment must be added for adequate glucose control.37
In advanced T3cDM, insulin replacement therapy is the only efficacious treatment option, and patients should be treated using general insulin dosing and regimen guidelines for T2DM.38 In T3cDM, blood glucose control may be labile because of loss of glucagon secretion, carbohydrate malabsorption, and/or inconsistent eating patterns due to pain and/or nausea. Insulin pump therapy should be considered for patients who are able to manage this form of treatment. In diabetes due to CP, therapy with insulin or insulin secretagogues (sulfonylurea and glinides) may be necessary. Because secretagogues can cause hypoglycemia, short-acting agents are preferred when meal ingestion is inconsistent. Adverse effects associated with thiazolidinediones and potential risks of incretin-based therapies (eg, glucagon-like peptide-1 [GLP-1] analogues and dipeptidyl peptidase-4 [DPP-4] inhibitors) should preclude their use in T3cDM outside the context of formal clinical trials. Because T3cDM has the same incidence of retinopathy as T2DM does,39 surveillance for microvascular disease should be conducted for T1DM and T2DM.
Discrimination of T3cDM From T2DM
Type 3c DM differs from T2DM by the loss of not only insulin from β-cells but also glucagon from α-cells and PP from pancreatic polypeptide (PP) and F cells, respectively. Patients with CP who have preexisting risk factors of T2DM, such as obesity, may have further difficulties with glucose homeostasis, and a system for differentiating T3cDM from T2DM is needed. Ewald and Bretzel35 suggested the following criteria for diagnosing T3cDM:
Proposed major criteria (all must be fulfilled):
- Presence of exocrine pancreatic insufficiency (according to monoclonal fecal elastase 1 test or direct function tests
- Pathological pancreatic imaging (EUS, MRI, and computed tomography [CT])
- Absence of T1DM-associated autoimmune markers
- Impaired β-cell function (eg, HOMA-B, C-peptide–glucose ratio)
- No excessive insulin resistance (eg, HOMA-IR)
- Impaired secretion of incretins (eg, GLP-1)
- Low serum levels of lipid-soluble vitamins (A, D, E, and K)
Despite these criteria, there is a degree of overlap between the different forms of diabetes because long-standing T1DM and T2DM are associated with exocrine pancreatic failure, and patients with diabetes are at a higher risk for developing AP and/or CP. Furthermore, patients with previous episodes of pancreatitis may develop T1DM or T2DM independently of their exocrine pancreatic disease. The best discriminator of T3cDM from T2DM seems to be the PP response to nutrients.38
Pancreatic polypeptide is localized predominantly to the islets in the ventral portion (head) of the pancreas and is promptly secreted in response to ingested nutrients. Type 3c DM secondary to cystic fibrosis, CP, pancreatic malignancy, or pancreatic resection is uniformly characterized by a deficiency in the nutrient-stimulated release of PP. Type 2 DM, on the other hand, is typically associated with an increase in basal and nutrient-stimulated levels of PP, and healthy elderly subjects with normal glucose tolerance also demonstrate elevations in basal and nutrient-stimulated levels of PP compared with younger subjects. Therefore, the discrimination of T3cDM from T2DM is based on the failure of plasma PP levels to increase after nutrient ingestion. Basal levels of PP in PP-deficient subjects are similar to basal levels in healthy subjects, so a nutrient stimulus is required to confirm PP deficiency. Glucose ingestion is a relatively weak stimulus for PP release, whereas a mixed nutrient meal is a strong inducer of PP release. A standardized mixed-nutrient stimulus is 8 oz of a liquid dietary supplement such as Boost or Ensure; peak levels of PP are seen within 30 to 60 minutes after ingestion.
Role of PP in T3cDM
Enhanced sensitivity to insulin administration, due to prevailing insulin deficiency, was a well-recognized consequence of pancreatogenic diabetes, but it was not until euglycemic clamp studies were performed with glucose tracer methodology that isolated hepatic insulin resistance was discovered to coexist in the setting of increased peripheral insulin sensitivity in animal and then clinical studies of T3cDM.37 Isolated hepatic insulin resistance has been documented in T3cDM due to CP, pancreatic resection, pancreatic cancer, and cystic fibrosis and results in persistent, unsuppressed hepatic glucose production. Pancreatic polypeptide deficiency has also been documented in CP,40 proximal or total pancreatectomy, and cystic fibrosis, so it was identified as a likely mediator of the hepatic defect. Acute administration of PP was found to have no effect on hepatic insulin sensitivity in healthy or PP-deficient individuals; however, prolonged PP administration was found to reverse the hepatic insulin resistance in rats, dogs, and patients with T3cDM due to CP or pancreatic resection. Animal studies confirmed that PP deficiency results in diminished hepatic IR availability, and hepatic IR deficiency is reversed by prolonged PP administration.37 In clinical studies, PP administration reversed hepatic insulin resistance in patients with CP or after proximal pancreatectomy and resulted in improved glucose tolerance. Recently, a randomized, placebo-controlled study in patients with T1DM and T3cDM found that PP administration enhanced insulin sensitivity and lowered the insulin requirements of these patients.41
Mechanism(s) of Pancreatic Cancer–Induced T3cDM
Although long-standing DM modestly increases the risk for PDAC, PDAC also frequently causes DM. This reverse causality has greatly complicated epidemiologic studies of the relationship between the 2 diseases.42 More than half of patients with PDAC have DM or hyperglycemia, and the onset of DM typically occurs between 6 months and 36 months before PDAC diagnosis in 20% to 25% of patients. Furthermore, resection of the PDAC leads to amelioration of DM in roughly half of subjects with new-onset DM.43 This suggests that new-onset DM could be a biomarker of PDAC.44
Hypotheses of How Pancreatic Cancer Induces T3cDM
As in T2DM, β-cell dysfunction and peripheral insulin resistance are seen in PDAC-induced DM (PDAC-DM). However, in contrast to T2DM, onset and progression of glucose intolerance in PDAC-DM occur in the face of ongoing, often profound, weight loss. There are several hypotheses for how PDAC might cause DM, including progressive pancreatic tissue destruction due to the tumor growth and metabolic consequences of cancer-related malnutrition. The most likely explanation for the frequent occurrence of DM in PDAC, however, is a paraneoplastic phenomenon caused by tumor-secreted products.45 This notion is supported by laboratory findings that supernatants from PDAC cell lines inhibit insulin secretion.
One such possible mediator of β-cell dysfunction in pancreatic cancer–induced diabetes is adrenomedullin, a pluripotent hormone with some homology to amylin, which is overexpressed in PDAC.46 Adrenomedullin receptors are found on β cells, and their expression is seen specifically in the F cells of the islets. Inhibition of insulin secretion was replicated by external addition of adrenomedullin and abrogated by its genetic knockdown. Similar effects were seen in orthotopic and subcutaneous in vivo tumor models using adrenomedullin-expressing PDAC cell lines.45 These findings support the notion that adrenomedullin is a mediator of β-cell dysfunction in PDAC. The cause(s) of insulin resistance and PDAC-DM–associated weight loss remains unclear, though these seem to be paraneoplastic phenomena as well.46
GENOMIC ASSOCIATIONS OF CP, DM, AND PDAC
After several decades of research, a roster of genes have been identified for CP, DM, and PDAC (Table 1), all 3 of which share 3 characteristics: familial aggregation and familial clustering, which are indicators of shared genetic and/or environmental etiologies; variation in age at diagnosis, which has been linked in some subsets of patients to familial risk; and a hereditary component, as demonstrated by Mendelian segregation analyses. For all 3, epidemiologic risk factors (eg, sex, obesity [DM], alcohol intake [CP], and smoking [PDAC]) may interact with genetic factors.
Variants of approximately 30 genes have been found to confer genetic risk for DM, each with a modest effect (eg, PPARG and KDNJ11, identified through the candidate gene approach, and TCF7L2, WFS1, HDF1B, FTO, CDKN2A, SLC20A8, among others, identified through association and GWAS approaches).47–50 Research to date suggests that susceptibility to DM is explained by a polygenic risk model, with each genetic variant having a small effect, and none of which significantly improves risk assessment over common risk factors such as age, sex, family history, body mass index (BMI), and clinical measures.51
Rather than a classic Mendelian disorder, recurrent AP and CP represent truly complex diseases with the interaction and synergism of multiple genetic and environmental factors, especially alcohol and smoking.52,53 However, much of the variability in susceptibility to recurrent AP and CP is now clearly shown to be related to genetic factors, with PRSS1, SPINK1, CTRC, CFTR, and CASR established as susceptibility loci for CP. Most recently, a large 2-stage GWAS analysis by Whitcomb et al7 identified and replicated PRSS1-PRSS2 and the X-chromosome–linked CLDN2 as susceptibility loci, with the latter gene’s variants potentially interacting with alcohol consumption.
For the past decade, the efforts of the Pancreatic Cancer Genetic Epidemiology Consortium, the Pancreatic Cancer Case-Control Consortium, and the PanScan have demonstrated that individuals with a family history of pancreatic cancer are at an increased risk for developing pancreatic cancer. Overall, case-control studies have estimated that the odds of having a family history of pancreatic cancer are 1.9- to 13-fold higher in patients with pancreatic cancer compared with healthy controls. A recent pooled analysis of data from 5 cohort studies and 1 case-control study estimated the odds of pancreatic cancer to be 1.76 higher among individuals with 1 first-degree relative (FDR) and 4.26 higher among those with 2 or more FDRs with pancreatic cancer compared with those without a family history of pancreatic cancer.54,55
A number of susceptibility genes have been identified.56 The most commonly mutated gene is BRCA2, with PALB2 as the second most commonly mutated gene for hereditary pancreatic cancer.57 Carrying a disease-associated mutation in CFTR is associated with a modest increase in risk for pancreatic cancer, with those affected generally diagnosed at a younger age, especially among smokers; interestingly, clinical evidence of antecedent pancreatitis was uncommon among both carriers and noncarriers of CFTR mutations.58 Next-generation sequencing studies indicate that inherited ATM mutations also play an important role in familial pancreatic cancer predisposition.59
GWAS studies of sporadic cases of pancreatic cancer have implicated regions that harbor ABO, TERT, and CLPTM1L. The results are consistent with earlier epidemiologic evidence suggesting that people with blood group O may have a lower risk for pancreatic cancer than those with groups A or B.60 Using GWAS data from 3851 cases and 3934 controls and a logistic regression model for genotype trend effect that was adjusted for study, age, sex, self-described ancestry, and 5 principal components, Petersen et al61 identified 8 SNPs that map to 3 loci on chromosomes 13q22.1, 1q32.1, and 5p15.33. Two correlated SNPs, rs9543325 and rs9564966, map to a nongenic region on chromosome 13q22.1. Five SNPs on 1q32.1 map to NR5A2, and the strongest signal was at rs3790844. A single SNP, rs401681, maps to the CLPTM1L-TERT locus on 5p15.33, which is associated with multiple cancers. Additional insights gained from pathway, candidate gene, and gene-environment studies are now possible.
SURVEILLANCE OF INDIVIDUALS WITH HIGH RISK FOR PANCREATIC CANCER
Radiologic and Cytogenetic Detection of Premalignant Lesions
Management of patients at high risk for PDAC is important yet difficult because of uncertainties regarding the method and the frequency of screening methods, as well as concerns about the potential harm from missing resectable and curable lesions, compared with the risk of removing lesions with low malignant potential. There have been numerous small screening studies performed in the United States and Europe during the last decade62–68 as well as ongoing studies of PDAC genetic epidemiology.69–71 Target lesions for pancreatic screening include T1 N0 M0 margin-negative PDAC, high-grade dysplastic precursor lesions such as PanIN-3, and intraductal papillary mucinous neoplasia with high-grade dysplasia. Screening and surveillance are also recommended for FDRs of patients with PDAC in at least 2 FDRs, patients with Peutz-Jeghers syndrome, and carriers of mutations in familial PDAC susceptibility genes (p16, BRCA2, PALB2, and HNPCC-associated genes) with at least 1 affected FDR. Pancreatic lesions are more common in older individuals, so screening should generally be initiated at age 50 or 55 years.69,70,72
The initial screening test for cystic lesions should include EUS and/or MRI/magnetic resonance cholangiopancreatography (MRCP) based upon the results of the CAPS3 trial that showed that EUS and MRI/MRCP had similar accuracy at detecting pancreatic cysts that exceeded the sensitivity of CT scanning.71 When PDAC is suspected, CT imaging using a pancreatic protocol is the best technique for evaluating solid lesions. Because of the risk for postprocedure pancreatitis, endoscopic retrograde cholangiopancreatography should be used only when there is a suspected neoplastic main duct lesion identified by EUS or MRI/MRCP.
Because PanIN lesions can be identified reliably only by histological analysis of pancreatic tissue, investigators have proposed several approaches to identify PanIN. One option involves performing pancreatic tail resections for patients with diffuse pancreatic imaging abnormalities and then proceeding to total pancreatectomy if PanIN-3 is detected.73,74 Other approaches are under investigation, including analysis of endoscopically collected pancreatic fluid for markers of PanIN-375,76 and molecular imaging approaches.77
Subjects with subcentimeter branch duct IPMNs identified by screening are currently recommended to undergo surveillance annually or more often, depending on the size of the lesion. For high-risk subjects with unifocal cysts or 1 dominant cyst with disturbing features (mural nodule, duct dilatation of several centimeters and increasing size), criteria for resection at many screening centers have evolved to be similar to the criteria used to manage sporadic lesions.78,79 There is no consensus on whether to perform partial or total pancreatectomy for suspicious lesions identified by screening. Patients who undergo a partial pancreatectomy are recommended to continue surveillance. Some centers will perform a completion total pancreatectomy if PanIN-3 is detected in the resection specimen rather than continue surveillance. Islet cell autotransplantation after total pancreatectomy is not recommended for patients with high risk for developing PDAC because of concerns of reintroducing neoplastic cells into the patient’s liver.
Biomarkers for Pancreatic Screening and Lesion Characterization
An obstacle to detecting small early-stage pancreatic cancers is that very small cancers may not produce a sufficient amount of material useful for a screening test. Improvements in diagnostic imaging are needed, such as molecular imaging tools that improve the discrimination of malignant cells from benign conditions such as plectin-based imaging.77
A variety of molecular targets are under investigation for their diagnostic utility in PDAC. Although gene mutations are a major focus of biomarker efforts at early detection, other biomarkers are under investigation including proteins,80 modified proteins such as glycoproteins, microRNAs,81 and other noncoding RNAs. The tumor antigen CA19-9 is a glycoprotein, and further investigation of glycosylation abnormalities and glycoprotein patterns may help identify diagnostic markers.82 Furthermore, many individuals develop antibodies to mutated proteins, overexpressed proteins, or altered forms of proteins that arise during malignant progression of cancer, and these autoantibodies may be useful biomarkers.83
The main clinical scenarios in which biomarkers are needed include the detection of asymptomatic T1 N0 M0 pancreatic cancers, the evaluation of pancreatic cysts, and the detection of PanINs. Although EUS-guided fine needle aspiration of solid masses has a high cytologic diagnostic yield, standard cytologic evaluation of pancreatic cyst fluid has limited value because of the paucity of cellular material in early noninvasive lesions and the limited diagnostic utility of current marker tests. Sequencing IPMN cyst fluid DNA for somatic mutations in candidate genes has led to the identification of oncogenic GNAS mutations in 66% of IPMNs, and this approach is a focus of current investigation.84
Cost-Benefit Analysis of Screening and Intervention in High-Risk Patients
The outcome measure of health services effectiveness is reported as quality-adjusted life-years, which combines the quantity and the quality of life into 1 single index. Quantity is defined as years of life, whereas quality is quantified through the concept of “utility,” which incorporates a patient’s preference for a specific state of health. Cost-effectiveness analysis is generally more useful when the diagnostic indications and tests and subsequent management are relatively agreed upon and standardized. Cost-effectiveness analysis studies have been performed in the setting of screening asymptomatic members of familial pancreatic cancer kindreds and illustrate that current knowledge gaps prevent cost-effectiveness determinations in pancreatic cancer screening.85
Because no consensus guideline for clinical use exists, screening is typically done in association with research studies linked to a registry and with protocol-directed collection of blood, urine, and/or pancreatic juice. Most academic centers recommend EUS every year starting at age 50 years or 10 years younger than the earliest age of onset in patients who are FDRs in familial pancreatic cancer syndromes and first- or second-degree relatives in gene carriers for diseases associated with an increased risk for PDAC and HP. Other centers use MRI instead of EUS. The rationale is that MRI seems to have similar sensitivity for cystic lesions, but because of volume averaging, small cancers may be missed, and cancers outside dominant cysts may also be missed. The frequency and the type of follow-up testing depend on the presence of high-risk biomarkers and comorbid conditions that may affect the decision for definitive treatment, such as total pancreatectomy.
THE EFFECTS OF DIABETES TREATMENT ON PDAC
In addition to diet and exercise, commonly used drugs to treat T2DM include sulfonylureas, metformin, thiozolidinediones, alpha-glucosidase inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors. In addition, there are various forms of insulin, including insulin glargine, a long-acting recombinant insulin that exhibits an increased binding affinity toward the insulin and insulin-like growth factor-1 receptors. Although several studies have suggested that insulin glargine may slightly increase the risk for certain cancers, including possibly PDAC, other studies have failed to show such an association. Sulfonylureas, thiozolidinediones, and alpha-glucosidase inhibitors seem to have little or no effect on the risk for PDAC.
Metformin is a biguanide that acts principally to decrease hepatic glucose output. Several retrospective studies of diabetic patients and 3 case-control studies of patients with pancreatic cancer have reported that metformin use is associated with a reduced risk for PDAC.86 It has also been reported that metformin use was associated with a longer overall survival time and lower mortality in patients with PDAC and DM and that metformin may help reduce the risk for PDAC.87 However, 2 cohort studies of diabetic patients did not confirm that metformin lowered the risk for pancreatic cancer. In view of the limitations of retrospective studies due to multiple potential biases, there is clearly a need for large-scale studies to assess the effects of metformin and other glucose-lowering agents on the pancreas.88
Mechanisms of Action of Incretins
Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide are intestinal-derived incretins that potentiate glucose-stimulated insulin secretion by the β cell, inhibit glucagon release by the α cell, and promote β-cell growth and survival. Glucagon-like peptide-1 acutely stimulates glucose-dependent insulin release through increased production of intracellular cyclic adenosine monophosphate and exerts chronic effects that prevent β-cell exhaustion by ensuring that insulin messenger RNA stability is increased and insulin stores are refilled. Glucagon-like peptide-1 also upregulates PDX-1 expression and induces its translocation to the nucleus, leading to enhanced insulin gene transcription.89 Glucagon-like peptide-1 also acts to suppress β-cell apoptosis. Thus, GLP-1 promotes β-cell proliferation and β-cell survival.90
Glucagon-like peptide-1 mimetics such as exendin-4 (exenatide) and liraglutide interact directly with the GLP-1 receptor, whereas DPP-4 inhibitors such as sitagliptin, saxagliptin, and linagliptin increase endogenous levels of GLP-1 by interfering with its DPP-4–mediated degradation. Glucagon-like peptide-1 receptors are expressed on various cell types, including β cells, pancreatic duct cells, pancreatic duct glands, acinar cells, and cells within PanIN lesions. Therefore, in addition to its effects on the β cells, GLP-1 can exert trophic effects on these other cell types. For example, GLP-1 may promote mitogenic signaling in human pancreatic ductal cells by activating the GLP-1 receptors on these cells. These observations underscore the importance of assessing the potential role of GLP-1 receptor agonists in the human pancreas.
Results From a Human Pancreatic Biobank Study
To explore this issue, a recent study examined autopsy-obtained pancreata derived from 7 patients with T2DM who had been treated with sitagliptin and 1 who had been treated with exenatide (a GLP-1 homologue).91 These pancreata were ∼40% larger than the pancreata from 12 donors with T2DM who had not been treated with incretin mimetics (control group). Cell proliferation and the frequency of PanIN lesions were increased in the incretin group compared with the control group. In addition, the incretin group exhibited α-cell hyperplasia and glucagon-expressing microadenomas (3/8) and 1 pancreas harbored a glucagon-expressing neuroendocrine tumor. By contrast, no glucagon-expressing microadenomas or neuroendocrine tumors were present in the pancreata from the control group.
These alterations, combined with more PanIN lesions adjacent to ducts, could potentially contribute to obstruction-associated alterations and pancreatitis during long-term incretin mimetic therapy. However, the incretin mimetic group was, on average, 18 years older than the control group, which may have affected the results because the incidence of PanIN lesions increases with age. The increased size of the pancreata in the incretin-treated cohort remains unexplained, but the effect was primarily due to inclusion of 2 morbidly obese men (BMI > 40) and a severely obese woman (BMI > 35) in the incretin mimetic group. In addition, the pancreas sizes were not controlled for sex (male pancreata tend to be larger) or visceral fat in the pancreas of obese subjects.92 Additional clinical studies are therefore required to assess the consequences of incretin mimetic therapy on the pancreas, especially because a study with diabetic rats suggested that GLP-1 may cause pancreatic abnormalities including pancreatic ductal hyperplasia93 and a study using a genetically engineered mouse model of pancreatic cancer in which oncogenic K-ras is expressed revealed that 12 weeks of treatment with Exendin-4 led to accelerated PanIN and desmoplastic progression.94
Industry Perspective on Pancreatitis and Pancreatic Cancer Risk With Liraglutide
Treatment of patients with T2DM with liraglutide, a long-acting GLP-1 receptor agonist, has not shown any evidence of a risk for pancreatitis or PDAC. Studies in mice, rats, and cynomolgous monkeys did not reveal any hyperplasia, PanINs, metaplasia, or endocrine tumors. Similarly, studies in diabetic Zucker rats did not reveal any drug-induced effects. In humans, in more than 6500 patients and greater than 5000 patient-year exposures, there were 2 patients with pancreatic cancer after 152 and 7 days of therapy, and a third patient was diagnosed with pancreatic cancer before randomization. With respect to AP, there was a 1.8-fold increase in incidence per 1000 patient-year exposure, which approximated the range anticipated in a population of individuals with T2DM (0.55–1.37 cases per 1000 patient-years). Interestingly, unrelated to therapy, lipase levels were increased in 20% of T2DM and fluctuated over time. Studies in mice, rats, and monkeys given high doses of liraglutide did not reveal any histological evidence for pancreatic inflammation or PanIN formation.
In humans, a causal relationship between liraglutide and AP or PDAC can neither be established nor excluded on the basis of current data. However, prospective, controlled, and independently adjudicated data are being collected from several ongoing clinical trials, including a large 9000-patient cardiovascular outcome trial (LEADER). Data from postmarketing safety surveillance and independently submitted reports to regulatory agencies during the last 3 to 4 years have not identified an association between liraglutide and pancreatic pathology. Two prospective epidemiologic studies, based on a claims database in the United States and a medical record database in the United Kingdom, are currently being conducted and will provide valuable additional information.
Industry Perspective on Pancreatitis and Pancreatic Cancer Risk With Sitagliptin
In studies with mice, rats, monkeys, and dogs, the DPP-IV inhibitor sitagliptin was not associated with any episodes of pancreatitis, gross alterations in the pancreas, or histomorphological changes in the pancreas. In humans, a post hoc analysis of reported adverse events of pancreatitis and pancreatic cancer was carried out using a pooled population of nearly 15,000 patients. Slightly more than half of these patients were randomized to receive sitagliptin (100 mg/d), for at least 12 weeks, with some patients receiving the drug for up to 2 years. To take into account potential differences between groups in relation to duration of exposure to treatment, reports of adverse events were expressed as exposure-adjusted incidence rates (numbers of patients with events per 100 patient-years). The mean duration of exposure was 284 days for the sitagliptin group and 264 days for the comparison group. For the composite endpoint of pancreatitis (which included the terms pancreatitis and pancreatitis acute), exposure-adjusted incidence rates were similar for both groups (0.08 and 0.09 events per 100 patient-years in the sitagliptin and comparator groups, respectively). A similar pattern was observed with an expanded composite that added the term pancreatitis chronic, with 0.13 and 0.09 events per 100 patient-years in the sitagliptin and comparison groups, respectively.95
For the composite endpoint of pancreatic cancer (including the terms adenocarcinoma of pancreas, pancreatic carcinoma, and pancreatic carcinoma metastatic), the exposure-adjusted incidence rates were similar in the 2 treatment groups (0.05 and 0.06 events per 100 patient-years in the sitagliptin and comparison groups, respectively). These data from sitagliptin clinical trials are consistent with a published meta-analysis of clinical trials involving multiple DPP-4 inhibitors.96 In view of the long latency period for the development of pancreatic cancer, data from longer-term studies are required. Such data will be available from a sitagliptin cardiovascular outcomes study of more than 14,000 patients (TECOS) and cardiovascular outcome studies with other DPP-4 inhibitors.
Pitfalls in Studies of Adverse Drug Effects
Given the large number of patients with T2DM who take antidiabetes medications on a long-term basis, any protective or harmful effects of these medications on cancer risk, even at a relatively modest magnitude, could have significant public health implications. Ideally, one should conduct randomized controlled trials (RCTs) to assess drug risk. Because the sample size and the follow-up duration are seldom sufficient for cancer outcomes in such studies, postmarketing surveillance is critical. This includes spontaneous adverse event reporting systems and formal phase 4 studies. However, spontaneous reporting is subject to reporting bias and rarely guides practice. Postmarketing RCTs may inform safety but are only occasionally available. Although observational studies involving large populations and extensive person-years of drug use are important phase 4 studies, these are prone to various biases. These include confounding by indication, as in the case of the choice of antidiabetes therapy being dictated by factors such as severity of diabetes. Smoking, diet, physical activity, compliance/adherence, and comorbidity status also need to be considered because these may influence cancer risk. Another concern is protopathic bias, which occurs when treatment of the early symptoms or other consequences of a disease seem to cause the disease. This is usually associated with an inverse duration-response effect between the exposure and the outcome and is of concern when evaluating the association between diabetes medications and pancreatic cancer. For example, a reported association between short-term exposure to antidiabetes medications and the risk for pancreatic cancer disappeared or was significantly decreased after longer duration of exposure. Incorporation of a lag time in exposure definition helps to control for protopathic bias.
Time-related biases are common and give the incorrect appearance that a medication reduces the risk for developing the outcome of interest. These include immortal time bias, in which treatment status involves a delay during which follow-up time is accrued; time-window bias in case-control studies due to differences in exposure opportunity time windows between cases and controls; and time-lag bias, which occurs when different classes of diabetes treatments are prescribed at different stages of diabetes. It is therefore important to use appropriate statistical methods that minimize these biases.
Food and Drug Administration Surveillance of Adverse Drug Effects
Investigational drugs are subject to extensive nonclinical testing, including 6- to 9-month studies in rodents and nonrodents, and 2-year evaluation of carcinogenicity in rats and mice. Although pancreatic toxicity or pancreatic neoplasms have not been observed with incretin mimetics, carcinogenicity studies revealed that acinar and islet hyperplasia or hypertrophy, inflammation, and acinar atrophy were occasionally present in treated animals. These changes were of minimal severity, and modest increases in either incidence or severity were observed only at the highest dose evaluated, which is severalfold higher than used in humans.
Because GLP-1–based therapeutics may exert adverse effects on the exocrine pancreas under pathophysiological conditions that predispose to pancreatitis, such as T2DM, the Food and Drug Administration (FDA) issued a postmarketing requirement (PMR) on the sponsors of exenatide, liraglutide, and sitagliptin to conduct a pancreatic toxicology study in a rodent model of T2DM. Three such studies that met the PMR criteria were submitted to the FDA for review, and none demonstrated a treatment-related adverse effect on exocrine histology or proliferation. Food and Drug Administration veterinary pathologists re-examined the histological slides from 1 of these studies and concluded that treatment could cause mild changes, such as periductal inflammation, islet degeneration, and intraluminal concretions.
The FDA also initiated research into identifying an experimental model that would enable a comparative toxicological assessment of potential pancreatic toxicity for investigational GLP-1–based therapies currently under development. Chemically induced models of pancreatic injury, Zucker diabetic fatty rats, and mice fed a standard or high-fat diet have thus far been investigated. Mice fed a high-fat diet and administered exenatide displayed a time- and dose-dependent exacerbation of acinar cell hyperplasia, atrophy, fibrosis, and increased periductal inflammation. The effect of exenatide was multifocal and associated with histological changes of minimal to moderate severity but not with any effects on animal morbidity or mortality. The FDA has continuously monitored the GLP-1–based therapies since initial approval of these 2 drug classes, and continued nonclinical investigation remains an important component of the FDA’s efforts to clarify the potential pancreatic toxicity of the GLP-1–based therapies.
The Food and Drug Administration’s Approach to Addressing a Pancreatic Safety Signal With Incretin Mimetics
The market share for incretin mimetics in T2DM therapy is roughly 10%, and there is insufficient information to characterize safety profiles for these drugs. Therefore, postmarket safety and surveillance are crucial, and the FDA Adverse Event Reporting System (AERS) is functioning well in this regard. Although pharmacovigilance and pharmacoepidemiology are used by the FDA to address pancreatic safety signals, there is also concern regarding published studies that suffer from limited power and incomplete validation. Cases of AP, including necrotizing and hemorrhagic pancreatitis in association with incretin therapy in T2DM, have been reported to AERS in the postmarketing setting, and a recent analysis of admissions for AP among diabetic subjects revealed an increased association with incretin-based therapies.97 Safety concerns regarding these drugs have therefore been the subject of multiple FDA reviews and labeling changes. Published data mining analyses of the publicly available AERS data raised concerns regarding the risk for AP, pancreatic cancer, and thyroid cancer in association with incretin mimetic therapy.98 Limitations of AERS data include underreporting, lack of an accurate population denominator and adequate control data, and inadequate clinical documentation. It is therefore not possible to calculate incidence rates and establish causality on the basis of such data. The FDA has therefore issued safety communications and added information in the important limitations of use subsection of the indications and usage section, the adverse reactions, the postmarketing subsection, and the patient counseling information section to warn patients of the risk for AP. The FDA has also required the manufacturers to conduct epidemiologic studies of pancreatic toxicity to confirm and quantify the potential association with GLP-1 therapies in T2DM and required that cases of pancreatitis and pancreatic cancer be reported as adverse events of special interest in large cardiovascular outcome trials that are required for the GLP-1–based therapies. The signal for medullary thyroid cancer, a rare form of thyroid cancer that has been observed in animal studies with long-acting GLP-1 agonists, is labeled in a boxed warning in all approved long-acting GLP-1 agonists (liraglutide and exenatide). Moreover, the FDA has required that all manufacturers of approved GLP-1 agonists participate in a Medullary Thyroid Cancer Registry as a PMR. Importantly, to date, a causal link between GLP-1–based therapies and the risk for AP has not been established, and evaluation of the potential association between GLP-1–based therapies and pancreatitis and pancreatic and thyroid cancers will require adequately powered, long-term epidemiologic studies.
GAPS AND OPPORTUNITIES FOR FURTHER RESEARCH
Gaps in our knowledge exist across the full spectrum of pancreatic cancer. The failure to diagnose PDAC at an early stage and an aggressive pattern of metastasis both contribute to the dismal outcomes with this disease. For this reason, continued emphasis should be placed on both early diagnosis and therapy. The major challenge for the future, given the incidence of this disease, is the development of strategies for early detection that focus on cost-effective and transportable tests to identify high-risk subjects.
Advancing the clinical care of patients with PDAC will require improving biorepositories and developing a road map to prioritize therapeutic targets in clinically relevant models. Therapeutic intervention in the adjuvant setting may be preferable to eliminate some of the challenges of drug development in the advanced disease setting.99 The emphasis must therefore be on performing well-designed phase 2 studies with uniform sets of basic entry and evaluation criteria with survival as a primary endpoint. Patients with either metastatic or locally advanced PDAC must be studied separately.100
Pancreatic Stellate Cell Studies
Despite the increasing recognition of the tumor microenvironment and tumor-stromal interactions as significant contributors to PDAC, there remain significant gaps in knowledge regarding the role of PSCs. The origin of PSCs is not clear, but some investigators have identified the bone marrow as a source of a proportion of PSCs found in the pancreas. Although many investigators have identified PSC-derived factors that promote PDAC, it is unclear which mechanisms are most critical to PDAC progression. Evidence suggests that PSCs play a role in metastasis, but the precise mechanisms are still lacking. The PDAC-associated stroma represents an attractive target for novel therapies, but recent attempts to inhibit the stroma to improve response to chemotherapy have failed in clinical trials. Whether the stroma of PDAC is a rational target for novel therapies and, if so, what the best strategy is to inhibit the stroma are issues yet to be resolved.
Cholecystokinin Receptor Studies
Because CCK receptors are expressed by PSCs and responsible in part for collagen production,101 will treatment with CCK receptor antagonists stop or prevent fibrosis in patients with CP? Because CCK receptors are overexpressed in PDAC, could CCK receptor antagonists be a reasonable preventative therapy in high-risk individuals? Are CCK signaling pathways reasonable potential targets for PDAC treatment? Do high-fat diets stimulate endogenous CCK release and subsequently stimulate growth of tumors via CCK receptors? What is the role of CCK in pancreatic regeneration, in cross talk between cells in the developing pancreas, and in malignant transformation?
The Role of CP in PDAC Development
If future epidemiologic studies of CP are to proceed, the clinical definition of CP needs to be carefully defined (ie, self-report vs clinician diagnosis) and the actual prevalence of CP needs to be established. In general, pancreatitis is considered as 3 basic categories—AP, recurrent AP, and CP—as part of a disease continuum. Further information is needed on the factors that determine progressing through such a continuum. Some microbes directly infect the pancreas, but it is unclear what role microbial components play in CP and PDAC. The cellular origin of PDAC remains unclear, and the factors that mediate ADM and the early initiation of PanIN formation need further examination. Acinar-to-ductal metaplasia has been observed in CP as well; will a better understanding of ADM increase our success in screening and prevention of PDAC? Epidemiologic studies are needed to determine whether patients with CP who present with (type 3c) diabetes should be screened and monitored for PDAC development. Can the specificity of screening be improved with multiple serial markers and tests (biomarkers, mutations, hypermethylation in pancreatic juice, markers of activation of PSCs) and imaging (EUS, other imaging, targeted imaging, computer-aided diagnosis)? It seems reasonable to imagine that multiple biomarkers and imaging technologies may improve the predictive ability to identify high-risk patients with CP, but which tests and how many tests will be necessary? Will such screening approaches in high-risk persons be cost-effective?
Pancreatic Screening and Markers of Pancreatic Neoplasia
There are numerous gaps in our understanding of the benefits and the potential risks of pancreatic screening. Further research is needed to improve the risk stratification of subjects undergoing pancreatic screening and to better identify nongenetic risk factors associated with PDAC. Continued screening of high-risk individuals will generate better estimates of the prevalence of different grades of IPMNs and PanINs and invasive cancers for different genetic and familial backgrounds and other risk factors. This information is needed to determine the most appropriate age to initiate screening and how often subjects should be screened. We also need to better understand the natural history of PanIN and IPMN lesions and to develop biomarkers and molecular imaging methods to reliably detect high-grade pancreatic neoplasia and early-stage invasive cancer.
Type 3c DM Diagnosis and Treatment Implications
Further studies are needed to evaluate the pathophysiology of T3cDM caused by CP, PDAC, pancreatic resection, and cystic fibrosis. Specific issues that require clarity include the best criteria for differentiating T3cDM from T2DM, an assessment of the incidence of T3cDM in PDAC and diabetic populations in general, and an assessment of the effect of various diabetic drug treatments on the subsequent risk for PDAC in patients with T3cDM. Additional studies are needed to establish a standard provocative agent for assessment of nutrient-stimulated hormone (eg, GLP-1 and PP) release in diabetic subjects so as to discriminate T3cDM from T2DM. Studies are also needed to determine how PP levels compare with other measures of β-cell function and insulin sensitivity in the development of T3cDM, as well as the possible role of PP in the treatment of T3cDM. An evaluation of the long-term glycemic control and rate of diabetes-associated complications of patients with T3cDM with early insulin treatment compared with oral therapy is also needed.
Diabetic Pharmacotherapy Associations With PDAC
Large consortium studies are needed to compare new-onset and long-duration diabetic populations to determine the effects of antidiabetic treatments on the risk for PDAC.
A randomized trial of incretin and other antidiabetic agents in subjects with T2DM is needed, with periodic imaging of pancreatic size, measurement of pancreatic enzyme and GLP-1 levels, and islet cell products such as chromogranin-A and glucagon. A multisite survey of autopsy findings in diabetic subjects, similar in design to the recent study by Butler et al,91 should be conducted.
SUMMARY AND CONCLUSIONS
Several themes emerged from the workshop. First, the relationship between pancreatitis, diabetes, and PDAC is complex, but complexity is confounded by reverse causality. Chronic pancreatitis can cause diabetes by destruction of the islets (type 3c), resulting in the loss of glucagon and PP in addition to insulin, with a high risk for hypoglycemia. The risks for T3cDM and CP are additive in HP, but the specific PDAC risk for T3cDM in epidemiology studies is not known because it has not been specifically measured.
Recent reports in the medical literature and lay press have raised major concerns about the risk for PDAC in patients taking GLP-1 agonists or DPP-4 antagonists. The reports are primarily case-control studies using existing databases and a small report of autopsy findings.91 The majority of the variation in case-control studies seemed to be related to the control groups. Patients with diabetes are at increased risk for PDAC regardless of treatment, and new-onset diabetes in an older population may be a biomarker of occult cancer, thereby confounding outcome measures. Prospective RCTs have not revealed any association between GLP-1 or DPP-4 agents and PDAC, although the duration of treatment was limited. In addition, animal studies including more than 18,000 animals using doses of GLP-1 agonists or DPP-4 antagonists that were many times higher than doses given to humans did not reveal any signal of either pancreatitis or PDAC or premalignant lesions at rates higher than that of controls—and these findings were independently confirmed by studies done by the FDA. Finally, the relationship between antidiabetic agents, PDAC, and the public welfare are the responsibility of the FDA, and the presentations on the process of evaluating medical reports, public concerns, animal data, and human trials are handled with vigilance and objectivity. To date, the FDA has not seen a convincing signal between the use of GLP-1 or DPP-4 agents and PDAC, but it continues to monitor new findings and carefully evaluates them.
The value of open exchange of ideas and information from multiple branches of medicine and academics, industry, and government was obvious to all in attendance. It is anticipated that the foundations established by this workshop will provide groundwork for many productive programs and projects that will optimize patient treatment and reduce suffering, especially the burden of disease caused by PDAC.
The authors thank the following workshop speakers, whose lecture synopses informed this summary: Randall Brand, MD; Teresa Brentnall, MD; F. Charles Brunicardi, MD; Peter C. Butler, MD; Marcia I. Canto, MD, MHS; Suresh T. Chari, MD; Josephine M. Egan, MD; Samuel Engel, MD; Nils Ewald, MD, PhD; Thomas M. Gress, MD; Michael A. Hollingsworth, PhD; B. Timothy Hummer, PhD; Rosa F. Hwang, MD; Solomon Iyasu, MD, MPH; Donghui Li, PhD; Albert B. Lowenfels, MD; Alan C. Moses, MD; Michael N. Pollak, MD; Vinciane Rebours, MD, PhD; Michael R. Rickels, MD, MS; Rachael Stolzenberg-Solomon, PhD, MPH, RD; Margaret A. Tempero, MD; and Yu-Xiao Yang, MD. The authors thank Michelle L. Kienholz at the University of Pittsburgh for the editorial assistance.